This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
NEON-1 was a phase 1, open-label, single-group study evaluating ALPN-202 in subjects with advanced malignancies.
| Feature | NEON-1 |
|---|---|
| ClinicalTrials.gov identifier | NCT04186637 |
| Study title | An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies |
| Status | TERMINATED |
| Condition | Advanced Solid Tumor; Lymphoma |
| Sponsor | Alpine Immune Sciences, Inc. |
| Sponsor type | INDUSTRY |
| Intervention | ALPN-202 (drug) |
2. Clinical Question
The central clinical question was whether ALPN-202 could be evaluated in subjects with advanced malignancies through a phase 1 treatment study focused on safety assessment.
Population
Subjects with advanced solid tumors or lymphoma.
Intervention
ALPN-202.
Comparator
No comparator arm was used.
Primary question
The primary endpoint assessed adverse events associated with study drug exposure.
3. Trial Design
Single group.
None.
Treatment.
1.
4. Endpoints
| Endpoint | Definition | Time Frame |
|---|---|---|
| Adverse Events | Type, incidence, and severity of adverse events as assessed by CTCAE | Up to 30 days after last dose of study drug |
5. Planned Analysis
The registry identifies adverse events as the primary endpoint. No posted statistical analyses are available in the ClinicalTrials.gov record.
For a phase 1 safety endpoint, analysis generally focuses on descriptive summaries of observed events, including event type, incidence, and severity classification. Because this study uses a single-group design, interpretation centers on characterization of safety observations rather than comparison of randomized treatment effects.
6. Statistical Methodology
Descriptive safety analysis
Adverse event endpoints are commonly summarized using counts and proportions of participants experiencing events. Severity grading frameworks such as CTCAE provide a standardized approach for describing toxicity intensity across participants.
This type of measure describes observed event frequency within the study population. It does not estimate comparative treatment benefit because there is no comparator group.
Single-arm study interpretation
Single-group phase 1 studies are designed differently from randomized comparative trials. Without a control group, observed events cannot be separated statistically into treatment-related effects versus background disease, prior therapy, or other clinical factors without additional contextual information.
7. Statistical Methods Explained
Why was a single-group design used?
Early-phase studies commonly use single-group designs when the primary objective is initial evaluation of a treatment rather than comparison against another intervention.
What does CTCAE assessment contribute?
CTCAE provides standardized terminology and severity grading so adverse events can be consistently classified.
Why are adverse events different from efficacy endpoints?
Safety endpoints describe observed tolerability and toxicity patterns. They do not directly measure whether a treatment improves disease outcomes.
Why is there no hazard ratio or treatment effect estimate?
A hazard ratio compares event rates between groups. NEON-1 does not include a comparator arm, so comparative effect estimates are not part of the registered design.
Why is sample size interpreted differently in phase 1 studies?
Phase 1 enrollment is generally intended to characterize early safety findings and guide further development rather than provide definitive comparative efficacy conclusions.
8. Limitations
- No comparator arm: the single-group design limits comparative interpretation.
- Safety-focused endpoint: adverse event summaries do not establish treatment efficacy.
- Small enrollment: uncommon events may not be observed in a limited study population.
- Generalizability: results apply to the studied population and eligibility criteria.
- No posted analyses: the ClinicalTrials.gov record does not report formal statistical analyses.
9. Why This Trial Matters Statistically
NEON-1 illustrates several important principles in early clinical development.
| Concept | How it appears in NEON-1 |
|---|---|
| Phase 1 methodology | Early evaluation of a treatment in advanced malignancies |
| Safety analysis | Adverse events assessed by CTCAE |
| Single-arm design | No randomized comparator group |
| Descriptive statistics | Safety endpoints are typically summarized by observed frequency and severity |
| Interpretation limits | Observed findings require appropriate context without randomized comparison |
10. Sources
- ClinicalTrials.gov record: NCT04186637
- PubMed: 39097413